BioSpace News Archive

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).

The Leukemia & Lymphoma Society® announced it has received $17 million from the Mike and Sofia Segal Family Foundation to advance the treatment of chronic myelomonocytic leukemia, a rare type of blood cancer.

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) announced that blinded data on cognitive, biomarker and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease (AD) were presented today as an oral presentation at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) in Boston, MA,

Enterra Medical, Inc., an innovator in treatments for people living with gastroparesis, announced today that the Enterra® II System has been granted MR Conditional approval from the United States Food and Drug Administration (FDA).

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing PIV5-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, announced the publication of positive Phase 1 clinical trial results of its intranasal RSV vaccine candidate BLB201 in Science Advances.

One of North America’s largest integrated research organizations strengthens leadership with Will Furness as CEO and Mike Petit as CFO

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal AGENT IDE clinical trial of the AGENT™ Drug-Coated Balloon (DCB).

Vesigen Therapeutics, Inc. today presented data highlighting the potential of the Company’s non-viral ARMM (ARrestin-domain 1 Mediated Microvesicles) technology to overcome fundamental delivery challenges that limit the clinical application of emerging treatment modalities.

MDxHealth SA, a commercial-stage precision diagnostics company, announced it will release its financial results for the third quarter and nine-month period ended September 30, 2023, after market close on Wednesday, November 8, 2023.

23andMe Holding Co., a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced that it will report financial results for the fiscal year 2024 second quarter after the market closes on Wednesday, November 8, 2023.